December 18, 2019. We can all agree that there is a need for better treatment options for patients with epithelioid sarcoma. We can also agree that new treatments still need to have a real and meaningful benefit to patients. Just as important, there needs to be enough information about this treatment option so that patients and their physicians can determine if the benefits outweigh the risks for each patient, so they can decide whether or not to try it. There can be differences of opinion on what would be a meaningful benefit and what is a likely risk, and those will vary for individual patients.
Read More »On Medical Treatments & Products
NCHR Testimony on Olaparib for the Treatment of Germline BRCA-Mutated Pancreatic Cancer
December 17, 2019. The limitations of this study make the evaluation of the risks and benefits associated with Olaparib for germline BRCA-mutated pancreatic cancer difficult.
Read More »NCHR Testimony on Vernakalant for Rapid Conversion of Recent-Onset Atrial Fibrillation (Afib)
December 10, 2019. The benefit Vernakalant for rapid conversion of recent-onset Afib might possibly provide to a subset of patients does not outweigh the serious risks associated with it.
Read More »NCHR Comments on Abuse Deterrent Formulations for Stimulant Medications
November 19, 2019. If FDA approves abuse deterrent formulations, the label should clearly describe the exact property demonstrated in studies.
Read More »NCHR Testimony on Research Needed on Immunological Responses to Metal in Implants
November 13, 2019. Dr. Diana Zuckerman describes the types of research needed to reduce harm from the metal and other substances in implanted devices, including joint replacements, cardiac implants, mesh, reproductive devices, and many other types of implants.
Read More »